Australia Approves Neffy Adrenaline Nasal Spray for Anaphylaxis Treatment

CSL Seqirus, part of leading Australian biotechnology company CSL, announced on 16 February 2026 that neffy adrenaline (epinephrine) nasal spray is now available and has been approved for use in Australia for the emergency treatment of anaphylaxis in adults and children 15kg+ and aged four years and over. The approval marks the first time in over 30 years that a new way of administering adrenaline has been approved in Australia.

Anaphylaxis occurs after exposure to an allergen, such as food, medications and insect bites and stings, and can be life threatening if not immediately treated with adrenaline. Adrenaline rapidly reverses the effects of the condition by reducing throat swelling, opening the airways, and maintaining heart function and blood pressure.

Australia has one of the highest documented rates of anaphylaxis hospital admissions in the developed world. Between 2015 and 2020, Australian public hospitals reported a 51% increase in emergency department presentations and a 35% increase in hospitalisations due to anaphylaxis. Anaphylaxis rates have increased over recent decades.

An allergist stated that the approval of neffy is very welcome as it gives patients and their doctors a nasal administration option and choice in managing their condition. Anaphylaxis is a difficult condition to manage with some patients reporting challenges. Neffy has been available for some time overseas and now patients in Australia will have access.

The Health Strategy and Advocacy Manager at Allergy & Anaphylaxis Australia said having a new treatment option which does not require injection will offer people at risk of anaphylaxis, and their treating doctor, the ability to choose an adrenaline device that best suits their needs from the range available. People have to be extremely mindful of everyday things – such as eating at restaurants, attending social events, travelling or enjoying time outdoors. For parents of children with allergies, normal life experiences need to be planned for, including sleepovers, play dates, parties, air travel and school camps.

Healthcare organisations are updating their resources and anaphylaxis education to include neffy. The CSL Seqirus Executive Medical Director stated that the company recognises the work by key Allergy Stakeholders in ensuring clinicians, consumers and school settings are prepared and supported for the introduction of neffy.

CSL has submitted an application for neffy to be subsidised and listed on the Pharmaceutical Benefits Scheme. The submission will be considered in March 2026. Neffy is a registered prescription medicine and can only be prescribed by a doctor. Common side effects reported following neffy include headache, nasal discomfort, throat irritation and feeling jittery. For information, contact CSL Seqirus on 1800 642 865 or visit www.cslseqirus.com.au.